Patents by Inventor Michael C. Heinrich

Michael C. Heinrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of identifying and treating individuals exhibiting mutant kit protein
    Patent number: 8247419
    Abstract: The invention described herein relates to methods of identifying and treating individuals with protein tyrosine kinase associated disorders that have, or may, become resistant to treatment with a kinase inhibitor such as imatinib due to a gain-of-function mutation in KIT tyrosine kinase.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: August 21, 2012
    Assignees: Bristol-Myers Squibb Company, Oregon Health and Science University, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Francis Y. Lee, Michael C. Heinrich
  • Platelet derived growth factor receptor alpha (PDGFRA) polypeptides comprising activating mutation(s)
    Patent number: 8202969
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: June 19, 2012
    Assignees: Oregon Health & Science University, U.S. Department of Veteran Affairs, Dana-Farber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET
    Publication number: 20110081730
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: December 3, 2010
    Publication date: April 7, 2011
    Inventors: MICHAEL C. HEINRICH, CHRISTOPHER C. CORLESS, JONATHAN A. FLETCHER, GEORGE D. DEMETRI
  • Nucleic acids encoding platelet derived growth factor receptor alpha (PDGFRA) activating mutations
    Patent number: 7875710
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 25, 2011
    Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans Affairs, Dana-Faber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
    Publication number: 20090280495
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Application
    Filed: May 14, 2009
    Publication date: November 12, 2009
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation
    Patent number: 7595154
    Abstract: This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: September 29, 2009
    Assignees: Oregon Health and Science University, Dana-Farber Cancer Institute, Brigham and Women's Hospital
    Inventors: Michael C. Heinrich, Christopher C. Corless, Jonathan A. Fletcher, George D. Demetri
  • Methods of identifying and treating individuals exhibiting mutant kit protein
    Publication number: 20090221601
    Abstract: The invention described herein relates to methods of identifying and treating individuals with protein tyrosine kinase associated disorders that have, or may, become resistant to treatment with a kinase inhibitor such as imatinib due to a gain-of-function mutation in KIT tyrosine kinase.
    Type: Application
    Filed: June 9, 2006
    Publication date: September 3, 2009
    Inventors: Francis Y. Lee, Michael C. Heinrich, Christopher L. Corless
  • Treatment of gastrointestinal stromal tumors
    Patent number: 6958335
    Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: October 25, 2005
    Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., Oregon Health & Science University
    Inventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
  • Treatment of gastrointestinal stromal tumors
    Publication number: 20040023976
    Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Type: Application
    Filed: August 11, 2003
    Publication date: February 5, 2004
    Inventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson